ESMO FAMILY SITES
ESMO Clinical Recommendations
The ESMO Clinical Recommendations (CR) are clinical guidelines intended to provide the user with a set of requirements for a basic standard of cancer care.
Each CR offers vital, evidence-based information for physicians, including the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up
ESMO Clinical Recommendations, May 2009: Vol. 20, Supplement No. 4Editorial
| ESMO Clinical Recommendations: using the easier and faster approach to oncology guidelines |
N. Pavlidis, H. Hansen, and R. Stahel | FULL TEXT |
Breast cancer
| Primary breast cancer | V. Kataja and M. Castiglione | FULL TEXT | |
| Locally recurrent or metastatic breast cancer | F. Cardoso and M. Castiglione | FULL TEXT | |
| BRCA in breast cancer | J. Balmaña, O. Díez and M. Castiglione | FULL TEXT |
Brain tumors
| Malignant glioma | R. Stupp and F. Roila | FULL TEXT |
Gynecologic tumors
| Newly and relapsed epithelial ovarian carcinoma |
S. Aebi and M. Castiglione | FULL TEXT | |
| Non-epithelial ovarian cancer | N. Colombo, M. Peiretti and M. Castiglione | FULL TEXT | |
| Cervical cancer | C. Haie-Meder, P. Morice and M. Castiglione | FULL TEXT | |
| Endometrial carcinoma | M. M. Baekelandt and M. Castiglione | FULL TEXT |
Gastrointestinal tumors
| Esophageal cancer | M. Stahl and J. Oliveira | FULL TEXT | |
| Gastric cancer | C. Jackson, D. Cunningham and J. Oliveira | FULL TEXT | |
| Pancreatic cancer | S. Cascinu and S. Jelic | FULL TEXT | |
| Hepatocellular carcinoma | S. Jelic | FULL TEXT | |
| Biliary cancer | F. Eckel and S. Jelic | FULL TEXT | |
| Primary colon cancer | E. Van Cutsem and J. Oliveira | FULL TEXT | |
| Familial colorectal cancer risk | H. F. A. Vasen, A. E. van der Meulen–de Jong, W. H. de Vos tot Nederveen Cappel and J. Oliveira |
FULL TEXT | |
| Rectal cancer | B. Glimelius and J. Oliveira | FULL TEXT | |
| Anal cancer | R. Glynne-Jones, J. Northover and J. Oliveira | FULL TEXT | |
| Advanced colorectal cancer | E. Van Cutsem and J. Oliveira | FULL TEXT | |
| Gastrointestinal stromal tumours | P. G. Casali, L. Jost, P. Reichardt, M. Schlemmer and J.-Y. Blay |
FULL TEXT |
Lung cancer
| Non-small-cell lung cancer | G. D'Addario and E. Felip | FULL TEXT | |
| Small-cell lung cancer | M. Sørensen and E. Felip | FULL TEXT | |
| Malignant pleural mesothelioma | R. A. Stahel and W. Weder | FULL TEXT |
Urogenital tumors
| Prostate cancer | A. Horwich, C. Parker and V. Kataja | FULL TEXT | |
| Invasive bladder cancer | J. Bellmunt, S. Albiol and V. Kataja | FULL TEXT | |
| Renal cell carcinoma | B. Escudier and V. Kataja | FULL TEXT | |
| Testicular seminoma | H.-J. Schmoll, K. Jordan, R. Huddart, M. P. Laguna, A. Horwich, K. Fizazi and V. Kataja |
FULL TEXT | |
| Testicular non-seminoma | H.-J. Schmoll, K. Jordan, R. Huddart, M. P. Laguna, A. Horwich, K. Fizazi and V. Kataja |
FULL TEXT |
Hematologic malignancies
| Multiple myeloma | J.-L. Harousseau and M. Dreyling | FULL TEXT | |
| Acute myeloblastic leukemia in adult patients |
M. Fey and M. Dreyling | FULL TEXT | |
| Chronic lymphocytic leukemia | B. Eichhorst, M. Hallek and M. Dreyling | FULL TEXT | |
| Chronic myelogenous leukemia | M. Baccarani and M. Dreyling | FULL TEXT | |
| Hodgkin's lymphoma | A. Engert, D. A. Eichenauer and M. Dreyling | FULL TEXT | |
| Diffuse large B-cell non-Hodgkin's lymphoma |
H. Tilly and M. Dreyling | FULL TEXT | |
| Gastric marginal zone lymphoma of MALT type |
E. Zucca and M. Dreyling | FULL TEXT | |
| Primary cutaneous lymphoma | R. Willemze and M. Dreyling | FULL TEXT | |
| Newly diagnosed and relapsed follicular lymphoma |
M. Dreyling | FULL TEXT |
Head and neck tumors
| Squamous cell carcinoma of the head and neck | L. Licitra and E. Felip | FULL TEXT | |
| Nasopharyngeal cancer | A. T. C. Chan and E. Felip | FULL TEXT |
Sarcomas and melanomas
| Cutaneous malignant melanoma | R. Dummer, A. Hauschild and G. Pentheroudakis | FULL TEXT | |
| Soft tissue sarcomas | P. G. Casali, L. Jost, S. Sleijfer, J. Verweij and J.-Y. Blay | FULL TEXT | |
| Osteosarcoma | S. Bielack, D. Carrle and P. G. Casali | FULL TEXT | |
| Ewing's sarcoma of the bone | M. Paulussen, S. Bielack, H. Jürgens and P. G. Casali | FULL TEXT |
Neuroendocrine tumors
| Differentiated thyroid cancer | F. Pacini, M. G. Castagna, L. Brilli and G. Pentheroudakis |
FULL TEXT | |
| Neuroendocrine bronchial and thymic tumors | K. Oberg and S. Jelic | FULL TEXT | |
| Neuroendocrine gastroenteropancreatic tumors | K. Oberg and S. Jelic | FULL TEXT | |
| Cancers of unknown primary site | E. Briasoulis, N. Pavlidis and E. Felip | FULL TEXT |
Supportive care
| Chemotherapy-induced nausea and vomiting | J. Herrstedt and F. Roila | FULL TEXT | |
| Erythropoiesis-stimulating agents in cancer patients |
D. Scrijvers and F. Roila | FULL TEXT | |
| Hematopoietic growth factors | J. Crawford, C. Caserta and F. Roila |
FULL TEXT | |
| Management of febrile neutropenia | F. Marti Marti, M. H. Cullen and F. Roila |
FULL TEXT | |
| Management of cancer pain | L. Jost and F. Roila | FULL TEXT | |
| Management of oral and gastrointestinal mucositis | D. E. Peterson, R.-J. Bensadoun and F. Roila |
FULL TEXT | |
| Cancer, fertility and pregnancy | G. Pentheroudakis, N. Pavlidis and M. Castiglione |
FULL TEXT | |
| Management of venous thromboembolism in cancer patients |
M. Mandalà, A. Falanga and F. Roila |
FULL TEXT |
Acknowledgements
The ESMO Guidelines Working Group acknowledges and thanks the people who have acted as reviewers for these ESMO Clinical Recommendations
Guidelines Working Group Members
Disclosures
The members of the Guidelines Working Group have made the following disclosures
Clinical Recommendations are not designed to replace extensive clinical practice guidelines or review articles, but rather to describe common standards of care.
The ESMO CR are updated annually by the ESMO Guidelines Working Group, who manages and supervises them, while the ESMO Faculty members perform reviews and provide further expert opinion.
Clinical guidelines are important for the development of oncology as a specialty and serve to achieve many important goals:
- reach and maintain a high common standard of care in medical practice for cancer patients and help clinicians to offer the best care
- disseminate knowledge by supporting the translation into many languages
- support negotiations with politicians, administrators and insurance companies regarding what level of care should be made available
- help patients to find information on the therapies they are undergoing



BACK TO TOP
PRINT THIS PAGE